EN中文
Home Page
About Us
Company Profile
Company Team
Scientific R&D
R&D
R&D Pipeline
Newsroom
News Center
Employee Corner
Contact Us
Join Us
13
2026.08
New Site, New Journey | Shibeikang’s New R&D Building Officially Opens, Ushering in a New Chapter o...
On August 12, Chengdu Shibeikang Biomedical Technology Co., Ltd. held a relocation ceremony in Chengdu to mark the official opening of its new R&D building. The...
07
2026.08
Shibeikang Attends Frost & Sullivan Summit 2026 and Receives “Global Cardiovascular, Cerebrovascula...
From August 4 to 5, 2026, Chengdu Shibeikang Biomedical Technology Co., Ltd. was invited to attend the 20th Frost & Sullivan Global Growth, Innovation and Leade...
24
2026.07
Shibeikang Showcases Core Pipeline and AI-Powered Drug Discovery Platform at BCVS 2026 and Asian Car...
In July 2026, Chengdu Shibeikang Biomedical Technology Co., Ltd. participated in the Basic Cardiovascular Sciences (BCVS) Scientific Sessions organized by the A...
24
2026.06
Groundbreaking Study Findings on SBK007 Presented at EAACI Congress 2026
From 12 to 15 June 2026, the preclinical study findings of SBK007, a novel next‑generation anti‑allergic agent independently developed by Chengdu Shibeikang Bio...
04
2026.06
ERS Congress 2026 | Shibeikang’s SBK001 Study Findings Selected for Presentation at the 2026 Europe...
On June 2, 2026, preclinical study results regarding SBK001—a novel multi-target candidate drug developed by Chengdu Shibeikang Biomedical Technology Co., Ltd....
12345678...1213下一页
About Us
Company ProfileCompany Team
Scientific R&D
R&DR&D Pipeline
Newsroom
News CenterEmployee Corner
Contact Us
Join Us
(86)028 - 8798 8946
Building 3B, Hope Cloud Business Park (Gaoxin Park), No. 20 Xixin Avenue, Gaoxin West District, Chengdu, Sichuan Province
WeChat official account

© 2025版权所有 成都施贝康生物医药科技有限公司 蜀ICP备19024419号-1 -川公网安备 51012402000471号

Design&Technology:Cloud Technology